Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Azacitidine
Related studies linked through entity extraction aliases.
Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of Azacitidine in Myelodysplastic Syndrome (MDS) Associated to Systemic Auto-immune and Inflammatory Disorders
- Status
- COMPLETED
- Phase
- PHASE2
A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)
- Status
- COMPLETED
- Phase
- PHASE1
Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia
- Status
- TERMINATED
- Phase
- PHASE1
Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)
- Status
- COMPLETED
- Phase
- PHASE1
Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS)
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
- Status
- COMPLETED
- Phase
- PHASE2
Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Study of Azacitidine and Durvalumab in Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE2
A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Status
- COMPLETED
- Phase
- PHASE2
Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- Status
- TERMINATED
- Phase
- PHASE3
An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)
- Status
- COMPLETED
- Phase
- PHASE2
A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy
- Status
- COMPLETED
- Phase
- PHASE3
Peptide Vaccination in Combination With Azacitidine for Patients With MDS and AML
- Status
- COMPLETED
- Phase
- PHASE1